NCT01406704

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Seoul St. Mary's Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).

Detailed description

Duration: 24 week-intervention Study Group: Four arms * Control: no intervention * Rosiglitazone: rosiglitazone (8 mg/day) * alpha-lipoic acid: alpha-lipoic acid (1800 mg/day) * Rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)

Conditions

• NASH (Non-alcoholic Steato-hepatitis)

Interventions

Type	Name	Description
DRUG	Rosiglitazone	Rosiglitazone (8 mg/day)
DRUG	alpha-lipoic acid	alpha-lipoic acid (1800 mg/day)
DRUG	Rosiglitazone/alpha-lipoic acid	combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)

Timeline

• Start date: 2004-01-01
• Primary completion: 2010-12-01
• Completion: 2013-12-01
• First posted: 2011-08-01
• Last updated: 2011-08-19